Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia

[1]  Y. Hayashi,et al.  Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non‐Down syndrome , 2017, Genes, chromosomes & cancer.

[2]  A. Simon.  Risk factors for and prevention of bloodstream infection in pediatric AML—The debate continues , 2017, Pediatric blood & cancer.

[3]  J. Gralla,et al.  Risk factors for bacteremia and central line–associated blood stream infections in children with acute myelogenous leukemia: A single‐institution report , 2017, Pediatric blood & cancer.

[4]  Heather L. Mulder,et al.  Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes , 2017, Nature Genetics.

[5]  M. Jarfelt,et al.  Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity? , 2016, British journal of haematology.

[6]  M. Jarfelt,et al.  Cardiac function in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO‐AML study , 2016, European journal of haematology.

[7]  S. Adachi,et al.  Acute myeloid leukemia in children: Current status and future directions , 2016, Pediatrics international : official journal of the Japan Pediatric Society.

[8]  D. Reinhardt,et al.  Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004 , 2016, Blood Cancer Journal.

[9]  J. Downing,et al.  The biology of pediatric acute megakaryoblastic leukemia. , 2015, Blood.

[10]  D. Jd,et al.  Pediatric AML: From Biology to Clinical Management , 2015 .

[11]  Jianxiang Wang,et al.  Long-term follow-up of homoharringtonine plus all-trans retinoic acid-based induction and consolidation therapy in newly diagnosed acute promyelocytic leukemia , 2015, International Journal of Hematology.

[12]  C. Zwaan,et al.  Pediatric AML: From Biology to Clinical Management , 2015, Journal of clinical medicine.

[13]  Jianmin Wang,et al.  Homoharringtonine and omacetaxine for myeloid hematological malignancies , 2014, Journal of Hematology & Oncology.

[14]  Jie Jin,et al.  Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience , 2011, Annals of Hematology.

[15]  G. Kaspers.  Pediatric acute myeloid leukemia , 2012, Expert review of anticancer therapy.

[16]  Jingyan Tang,et al.  Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China , 2011, International journal of hematology.

[17]  G. Levitt,et al.  Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United Kingdom , 2011, Pediatric blood & cancer.

[18]  Liu-fang Gu,et al.  Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia , 2011, Journal of Cancer Research and Clinical Oncology.

[19]  Wendy Leisenring,et al.  Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. , 2008, Journal of the National Cancer Institute.

[20]  Jie Jin,et al.  Homoharringtonine affects the JAK2‐STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells , 2008, European journal of haematology.

[21]  Jian Huang,et al.  Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia , 2006, Leukemia.

[22]  Jingyue Tang,et al.  Homoharringtonine: A New Treatment Option for Myeloid Leukemia , 2004, Hematology.

[23]  D. Reinhardt,et al.  Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93 , 2004, Leukemia.

[24]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Chen,et al.  A homoharringtonine-based regimen for childhood acute myelogenous leukemia. , 2003, Medical and pediatric oncology.

[26]  R. Wenzel,et al.  Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  B. Cheson,et al.  Homoharringtonine , 2001, Cancer.

[28]  M. Chang,et al.  A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study. , 2001, Medical and pediatric oncology.

[29]  B. Cheson,et al.  Homoharringtonine , 2001 .

[30]  B. Cheson,et al.  Homoharringtonine: history, current research, and future direction. , 2001, Cancer.

[31]  C. Pui,et al.  Late effects of treatment in survivors of childhood acute myeloid leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  N. Young.  Immune pathophysiology of acquired aplastic anaemia , 1996, European journal of haematology. Supplementum.

[33]  T. Ahmed,et al.  Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. , 1992, Leukemia.

[34]  P. Steinherz,et al.  Phase I trial of homoharringtonine in children with refractory leukemia. , 1987, Cancer treatment reports.

[35]  D. Weisleder,et al.  Structures of harringtonine, isoharringtonine, and homoharringtonine. , 1970, Tetrahedron letters.